C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1) (pTyr245) antibody

Details for Product No. ABIN389502
Request Want additional data for this product?

The Independent Validation Initiative strives to provide you with high quality data. Find out more

 
Antigen
Synonyms ABL, JTK7, p150, c-ABL, v-abl, bcr/abl, AI325092, Abl, E430008G22Rik, c-Abl, ABL1, CABL, ABLL, cb272
Epitope
pTyr245
(45), (35), (31), (25), (23), (17), (14), (13), (13), (13), (12), (12), (12), (12), (12), (12), (12), (12), (11), (6), (6), (4), (3), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
Reactivity
Human, Mouse (Murine)
(472), (336), (286), (204), (194), (180), (60), (48), (1), (1), (1)
Host
Rabbit
(460), (20)
Clonality (Clone)
Polyclonal ()
Conjugate
Un-conjugated
(23), (20), (20), (19), (19), (19), (19), (19), (19), (19), (19)
Application
Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)
(255), (190), (169), (116), (89), (41), (18), (11), (11), (2)
Pubmed 5 references available
Catalog no. ABIN389502
Quantity 400 µL
Price
291.50 $   Plus shipping costs $45.00
Options
Shipping to United States (Change)
Availability Will be delivered in 2 to 3 Business Days

Order hotline:

  • +1 404 474 4654
  • +1 888 205 9894 (TF)
Immunogen This ABL1 Antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y245 of human ABL1.
Clone RB7349
Isotype Ig
Specificity This Phospho-ABL1-Y245 antibody is generated from rabbits immunized with a KLH conjugated synthetic phosphopeptide corresponding to amino acid residues surrounding Y245 of human ABL1.
Purification This antibody is purified through a protein A column, followed by peptide affinity purification.
Alternative Name ABL1
Background ABL1 is a cytoplasmic and nuclear protein tyrosine kinase that has been implicated in processes of cell differentiation, cell division, cell adhesion, and stress response. Activity of c-Abl protein is negatively regulated by its SH3 domain, and deletion of the SH3 domain turns ABL1 into an oncogene. The t(9,22) translocation results in the head-to-tail fusion of the BCR and ABL1 genes present in many cases of chronic myelogeneous leukemia. The DNA-binding activity of the ubiquitously expressed ABL1 tyrosine kinase is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function for ABL1.
Synonyms: Proto-oncogene tyrosine-protein kinase ABL1, p150, c-ABL, Abelson murine leukemia viral oncogene homolog 1, ABL1, ABL, JTK7,
Molecular Weight 122873 DA
Gene ID 25
UniProt P00519
Research Area Apoptosis/Necrosis, Phospho-specific antibodies, Cell Signaling, Protein Modifications, Cancer, Cell Cycle, Cell Structure
Application Notes WB = 1:1000, IHC = 1:50-100, IF = 1:10-50
Restrictions For Research Use only
Format Liquid
Concentration 0.45 mg/mL
Buffer PBS with 0.09 % (W/V) sodium azide
Preservative Sodium azide
Storage 4 °C/-20 °C
Storage Comment Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.
Expiry Date 6 months
Supplier Images
anti-C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1) (pTyr245) antibody Western blot analysis of anti-ABL Pab (ABIN389502) in mouse colon tissue lysate (35 µg/lane). ABL(arrow) was detected using the purified polyclonal antibody (1:30 dilution).
anti-C-Abl Oncogene 1, Non-Receptor tyrosine Kinase (ABL1) (pTyr245) antibody (2) Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. BC = breast carcinoma. HC = hepatocarcinoma
Background publications Aichberger, Mayerhofer, Krauth et al.: "Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides." in: Blood, Vol. 105, Issue 8, pp. 3303-11, 2005 (PubMed).

Wei, Li, Liu: "Insights into selective activation of p53 DNA binding by c-Abl." in: The Journal of biological chemistry, Vol. 280, Issue 13, pp. 12271-8, 2005 (PubMed).

Robinson, Martineau, Harris et al.: "Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia." in: Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K, Vol. 19, Issue 4, pp. 564-71, 2005 (PubMed).

Kim, Cho, Yoon et al.: "Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH." in: Genes, chromosomes & cancer, Vol. 43, Issue 1, pp. 37-44, 2005 (PubMed).

Barnes, McIntosh, Whetton et al.: "Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation." in: Oncogene, Vol. 24, Issue 20, pp. 3257-67, 2005 (PubMed).

Hosts (460), (20)
Reactivities (472), (336), (286), (204), (194), (180), (60), (48), (1), (1), (1)
Applications (255), (190), (169), (116), (89), (41), (18), (11), (11), (2)
Conjugates (23), (20), (20), (19), (19), (19), (19), (19), (19), (19), (19)
Epitopes (45), (35), (31), (25), (23), (17), (14), (13), (13), (13), (12), (12), (12), (12), (12), (12), (12), (12), (11), (6), (6), (4), (3), (2), (2), (2), (2), (2), (2), (2), (2), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1), (1)
back to top